Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BRIAN FRANCIS CHAPIN and THARAKESWARA K BATHALA.
BRIAN FRANCIS CHAPIN
Connection Strength
2.193
THARAKESWARA K BATHALA
  1. Whole-body MRI for staging prostate cancer: a narrative review. BJU Int. 2024 Sep 22.
    View in: PubMed
    Score: 0.247
  2. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2024 Sep 17.
    View in: PubMed
    Score: 0.247
  3. Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol. 2024 May; 25(5):617-618.
    View in: PubMed
    Score: 0.240
  4. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358.
    View in: PubMed
    Score: 0.194
  5. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306.
    View in: PubMed
    Score: 0.190
  6. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673.
    View in: PubMed
    Score: 0.183
  7. Imaging and Management of Prostate Cancer. Semin Ultrasound CT MR. 2020 Apr; 41(2):207-221.
    View in: PubMed
    Score: 0.180
  8. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.
    View in: PubMed
    Score: 0.174
  9. Management of cT4 Prostate Cancer. Eur Urol Focus. 2020 03 15; 6(2):221-226.
    View in: PubMed
    Score: 0.172
  10. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol. 2024 01; 25(1):66-83.
    View in: PubMed
    Score: 0.059
  11. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 06 01; 9(6):825-834.
    View in: PubMed
    Score: 0.056
  12. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int. 2023 09; 132(3):307-313.
    View in: PubMed
    Score: 0.056
  13. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer. 2022 03; 4(2):e210091.
    View in: PubMed
    Score: 0.052
  14. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology. 2022 04; 303(1):110-118.
    View in: PubMed
    Score: 0.051
  15. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med. 2020 May; 45(5):349-355.
    View in: PubMed
    Score: 0.046
  16. Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.